Login to Your Account

Financings Roundup

Dynavax Prices $39M Offering As Heplisav Finishes Phase III

By Trista Morrison

Friday, October 29, 2010
On a fundraising roll, Dynavax Technologies Corp. priced a $39. 1 million public stock offering as beleaguered hepatitis B vaccine Heplisav wraps up its final Phase III trials and marches toward a biologics license application filing next year. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription